Related Experiment Video
Updated: Dec 15, 2025
Live Imaging and Quantification of Viral Infection in K18 hACE2 Transgenic Mice Using Reporter-Expressing Recombinant SARS-CoV-2
Published on: November 5, 2021
Alternative management of Covid-19 infection
1Retired Consultant Haematologist (No Hospital Affiliation at Present).
Insights
Cytokine storm, a severe COVID-19 complication, lacks a defined treatment. This study proposes immune-modulating therapies like IV immunoglobulin, Rituximab, and thalidomide to reduce mortality and improve pandemic management.
Area of Science:
- Immunology
- Virology
- Critical Care Medicine
Background:
- Cytokine storm is a dangerous hyperinflammatory immune response complicating COVID-19.
- This condition leads to excessive cytokine production and is associated with high mortality.
- Currently, no universally accepted treatment exists for cytokine storm.
Purpose of the Study:
- To propose established immune-modulatory agents for treating COVID-19-induced cytokine storm.
- To highlight the potential of intravenous immunoglobulin, Rituximab, and thalidomide.
- To advocate for clinical trials to assess these agents' safety and efficacy.
Main Methods:
- Literature review of immune-modulatory agents used in inflammatory disorders.
- Proposal of high-dose intravenous immunoglobulin, Rituximab, and thalidomide for cytokine storm.
- Recommendation for randomized controlled clinical trials to evaluate proposed treatments.
Main Results:
- The proposed agents possess proven immune-modulatory properties.
- These therapies are already in use for various inflammatory conditions.
- Potential for reduced mortality and altered pandemic management.
Conclusions:
- High-dose intravenous immunoglobulin, Rituximab, and thalidomide are promising candidates for cytokine storm treatment.
- Randomized controlled trials are essential to validate their safety and efficacy.
- Successful treatment could significantly impact COVID-19 patient outcomes and pandemic control.
Abstract:
Cytokine storm is a life-threatening complication of Covid-19 infection. Excessive cytokines are the products of hyperactive immune inflammatory response mounted by the host against the virus. There is no agreed treatment for cytokine storm. Three therapeutic agents with proven immune-modulatory properties in regular use in a wide range of inflammatory disorders (high dose intravenous immunoglobulin, Rituximab and thalidomide) are proposed for the treatment of cytokine storm. Safety and efficacy of the proposed treatment should be assessed by randomised controlled clinical trials. The use of the proposed treatment is expected to reduce the mortality rate and alter the overall management of the pandemic.
More Related Videos
04:03Author Spotlight: Evaluating the Therapeutic Efficacy of Moving Cupping Along Meridians for Acute Exacerbation of COPD
Published on: September 27, 2024
08:52Generation of Multivirus-specific T Cells to Prevent/treat Viral Infections after Allogeneic Hematopoietic Stem Cell Transplant
Published on: May 27, 2011
Related Concept Videos
01:14Myocarditis III: Medical Management
01:28Pneumonia IV: Management
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
01:18Endocarditis III: Medical Management
01:29Chronic Obstructive Pulmonary Disease-V: Management
Smoking Cessation
01:25Transmission-based Precautions II: Airborne and Protective Environment
Airborne precautions:
Use airborne precautions when treating patients known or suspected to have diseases that spread through the air—for example, tuberculosis or measles. These organisms are present in smaller droplets expelled by an infected person and...
01:26COPD: Management Using Bronchodilators and Corticosteroids